<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618667</url>
  </required_header>
  <id_info>
    <org_study_id>SMC2017-06-111</org_study_id>
    <nct_id>NCT03618667</nct_id>
  </id_info>
  <brief_title>GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification</brief_title>
  <official_title>A Phase II Clinical Study of GC1118 in Recurrent Glioblastoma Patients With High Epidermal Growth Factor Receptor (EGFR) Amplification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent
      glioblastoma patients who were treated with standard concurrent chemoradiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent
      glioblastoma patients who were treated with standard concurrent chemoradiation.

      GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle)
      up to 6 cycles.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at 6 months</time_frame>
    <description>survival time from screening to progression defined by RANO criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>6 months, 12 month</time_frame>
    <description>survival time from screening to death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>up to 30months</time_frame>
    <description>best overall response rate defined by RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploration of predictive/prognostic biomarkers</measure>
    <time_frame>up to 30 months</time_frame>
    <description>according to NGS-based biomarkers(whole exome sequencing and whole transcriptome sequencing)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Glioblastoma, Adult</condition>
  <condition>EGFR Amplification</condition>
  <arm_group>
    <arm_group_label>single group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle) up to 6 cycles, or till progression or uncontrolled toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC1118</intervention_name>
    <description>GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.</description>
    <arm_group_label>single group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. written informed consent

          2. 19 years or older

          3. patients who experience recurrence following the standard therapy (CCRT, adjuvant
             temozolomide)

          4. high EGFR amplification

          5. available archive tumor sample(s)

          6. Karnofsky performance status (KPS) &gt; 70

          7. life expectancy &gt; 3 months

          8. adequate end-organ function

          9. patients who recovered from previous therapy (NCI CTCAE v4.03 Gr 1)

        Exclusion Criteria:

          1. patients who had EGFR target agent(s) before screening

          2. patients who have clinically significant cardiopulmonary dysfunction (cardiovascular
             disease (&gt; 2grade, NYHA), myocardial infarction within previous 3 months, unstable
             angina, unstable arrythmia, clinically significant interstitial lung disease)

          3. patients who had major surgery, open biopsy, or clinically significant trauma within
             previous 4 weeks

          4. patients who had investigation drug(s) within previous 4 weeks

          5. patients who had other malignancy(ies) within previous 3 years (except malignancies
             with low tendency to metastases or mortality for example, treated cervical
             intraepithelial neoplasia, skin cancer except melanoma, localized prostate cancer)

          6. patients who had severe infection within previous 4 weeks

          7. HIV infection

          8. patients who had anti-cancer therapy (surgery, chemo-radiation, chemotherapy,
             radiation therapy) within previous 4 weeks

          9. clinically significant liver disease (active hepatitis B viral (HBV) or hepatitis C
             viral (HCV) infection, alcoholic liver disease etc)

         10. pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>sehoon lee, professor</last_name>
    <role>Study Director</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>sehoon lee, professor</last_name>
    <phone>02-2148-9732</phone>
    <email>sehoon.lee119@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>dohyun nam, professor</last_name>
    <phone>02-2148-9732</phone>
    <email>nsnam@skku.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se-Hoon Lee, MD, PhD</last_name>
      <phone>+82-10-4759-7640</phone>
      <email>sehoon.lee@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Se-Hoon Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

